Ramalingam, S., Blackhall, F., Krzakowski, M., Barrios, C., Park, K., Bover, I., . . . Boyer, M. (2012). Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Chicago Style (17th ed.) CitationRamalingam, S., et al. Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients with Advanced Non-small-cell Lung Cancer. 2012.
MLA引文Ramalingam, S., et al. Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients with Advanced Non-small-cell Lung Cancer. 2012.